NFE2L2 and cancer: To determine the feasibility of AKR1B10 as a biomarker for NRF2 activation across different malignancies, we exploited The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE) multilevel data.